Open AccessCheckpoint inhibitors in advanced nonsmall-cell lung cancer; a Bayesian network meta-analysis
Author(s) -
Hakan Bozcuk,
Mustafa Yıldırım,
Özlem Nuray Sever,
Hasan Mutlu,
Mehmet Artaç
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_450_19
Subject(s) - oncology , medicine , hazard ratio , lung cancer , meta analysis , clinical endpoint , chemotherapy , pembrolizumab , cancer , confidence interval , clinical trial , immunotherapy
Checkpoint inhibitors (CPIs) have improved survival compared to chemotherapy alone in advanced nonsmall-cell lung cancer (NSCLC). This article aims to compare indirect evidence and rank the effect of different CPIs in this setting.